These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25333487)

  • 1. Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.
    Mo G; Gibbons F; Schroeder P; Krzyzanski W
    PLoS One; 2014; 9(10):e109747. PubMed ID: 25333487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach.
    Terranova N; Tosca EM; Borella E; Pesenti E; Rocchetti M; Magni P
    J Theor Biol; 2018 Aug; 450():1-14. PubMed ID: 29680449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKPD modeling of acquired resistance to anti-cancer drug treatment.
    Eigenmann MJ; Frances N; Lavé T; Walz AC
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):617-630. PubMed ID: 29090407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
    Tate SC; Cai S; Ajamie RT; Burke T; Beckmann RP; Chan EM; De Dios A; Wishart GN; Gelbert LM; Cronier DM
    Clin Cancer Res; 2014 Jul; 20(14):3763-74. PubMed ID: 24850847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
    Simeoni M; Magni P; Cammia C; De Nicolao G; Croci V; Pesenti E; Germani M; Poggesi I; Rocchetti M
    Cancer Res; 2004 Feb; 64(3):1094-101. PubMed ID: 14871843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Non-linear Mathematical Model for the Prediction of the Activity of a Putative Anticancer Agent in Human-to-mouse Cancer Xenografts.
    Liliopoulos SG; Stavrakakis GS; Dimas KS
    Anticancer Res; 2020 Sep; 40(9):5181-5189. PubMed ID: 32878806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
    Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
    J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
    Chen J; Smith M; Kolinsky K; Adames V; Mehta N; Fritzky L; Rashed M; Wheeldon E; Linn M; Higgins B
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):651-9. PubMed ID: 16937104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
    Sardu ML; Poggesi I; De Nicolao G
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models.
    Chandra F; Zaks L; Zhu A
    AAPS J; 2019 Jan; 21(2):16. PubMed ID: 30627814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
    Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
    BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
    Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
    Wu Q; Li MY; Li HQ; Deng CH; Li L; Zhou TY; Lu W
    Acta Pharmacol Sin; 2013 Nov; 34(11):1427-36. PubMed ID: 24096601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
    Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.
    Zwep LB; Duisters KLW; Jansen M; Guo T; Meulman JJ; Upadhyay PJ; van Hasselt JGC
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):350-361. PubMed ID: 33792207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
    Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
    Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma models.
    Chen X; Ji P; Yang HW; Yang LL; Zhou S; Zhong L; Ma S; Fu XY; Zhou C; Li GB; Zheng MW; Wei YQ; Yang SY
    Cell Physiol Biochem; 2013; 32(1):138-53. PubMed ID: 23867251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
    MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.